{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:47:26Z","timestamp":1787950046590,"version":"build-2784847793"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Understanding the posttreatment prognosis of skin lesions in patients with psoriasis is essential for improving patients\u2019 treatment satisfaction.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To model the prognosis of skin lesions for patients with psoriasis after 3 types of therapy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective cohort study included patients with psoriasis who visited a dermatologist and were enrolled in the platform of the Psoriasis Standardized Diagnosis and Treatment Center in China from August 2020 to December 2021.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Biologic, traditional, and systemic therapy for psoriasis.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Skin lesions were measured by the Investigator\u2019s Global Assessment (IGA) scale subsumed into 4 stages of severity (IGA 0\/1, IGA 2, IGA 3, and IGA 4), with higher scores indicating higher severity. The matching method was used to balance baseline covariates between patients receiving each of the 3 treatments. Transition probabilities from IGA scores at baseline to 0 to 1 month and 1 to 12 months were estimated.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 8767 patients were included in the final analysis (median age, 38.6 years [IQR, 28.7-52.8 years]; 5809 [66.3%] male). Across the 3 therapies, as the follow-up duration increased, the probability of improvement transition into a less severe IGA stage (from IGA 4 to IGA 0\/1) increased from 0.19 (95% CI, 0.18-0.21) in 0 to 1 month to 0.36 (95% CI, 0.34-0.37) in 1 to 12 months. Biologic therapy was associated with greater improvement transitions for severe conditions, with transition probabilities from IGA 4 to IGA 0\/1 increasing by 0.06 (95% CI, 0.02-0.09) vs traditional therapy and by 0.06 (95% CI, 0.03-0.09) vs systemic therapy in 0 to 1 month and by 0.08 (95% CI, 0.04-0.12) vs traditional therapy and 0.11 (95% CI, 0.07-0.14) vs systemic therapy in 1 to 12 months.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study modeling psoriasis prognosis provided a complete prognosis of skin lesions, and biologic therapy was associated with improved prognosis of moderate to severe psoriasis compared with traditional and systemic therapies. The study provides insight on using transition diagrams to assess psoriasis prognosis and to communicate with patients in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.6795","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T15:04:41Z","timestamp":1680793481000},"page":"e236795","source":"Crossref","is-referenced-by-count":8,"title":["Modeling Posttreatment Prognosis of Skin Lesions in Patients With Psoriasis in China"],"prefix":"10.1001","volume":"6","author":[{"given":"Zhihui","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Peking University First Hospital, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Han","sequence":"additional","affiliation":[{"name":"School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"},{"name":"Beijing International Center for Mathematical Research, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[{"name":"Beijing International Center for Mathematical Research, Peking University, Beijing, China"},{"name":"School of Mathematics and Statistics, Beijing Technology and Business University, Beijing, China"},{"name":"Research Center for Consumption Big Data and Intelligent Decision-Making, Beijing Technology and Business University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Peking University First Hospital, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Peking University First Hospital, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing International Center for Mathematical Research, Peking University, Beijing, China"},{"name":"Department of Biostatistics, School of Public Health, Peking University, Beijing, China"},{"name":"National Engineering Laboratory of Big Data Analysis and Applied Technology, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Peking University First Hospital, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"},{"name":"Peking University\u2013Yunnan Baiyao International Medical Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"issue":"9583","key":"zoi230227r2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis.","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"10281","key":"zoi230227r3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"zoi230227r4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","article-title":"Genital psoriasis is associated with significant impairment in quality of life and sexual functioning.","volume":"72","author":"Ryan","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"zoi230227r5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries.","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"8","key":"zoi230227r6","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.","volume":"146","author":"Kurd","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"zoi230227r7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis.","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"zoi230227r8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","article-title":"Patient-relevant treatment goals in psoriasis.","volume":"308","author":"Blome","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"zoi230227r9","first-page":"667","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition).","volume":"52","author":"Committee on Psoriasis, Chinese Society of Dermatology","year":"2019","journal-title":"Zhonghua Pifuke Zazhi"},{"issue":"10","key":"zoi230227r10","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"zoi230227r11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2147\/PPA","article-title":"Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis.","volume":"9","author":"Zhang","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"zoi230227r12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jdv.2011.25.issue-s4","article-title":"Maximizing patient adherence for optimal outcomes in psoriasis.","volume":"25","author":"Bewley","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"zoi230227r13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials.","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi230227r14","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.14237","article-title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).","volume":"31","author":"Menter","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"zoi230227r15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jdv.2018.32.issue-1","article-title":"Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.","volume":"32","author":"Paul","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"zoi230227r16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.2019.33.issue-2","article-title":"Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.","volume":"33","author":"Sawyer","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"zoi230227r17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjd.v183.4","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"zoi230227r18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2021.0734","article-title":"Long-term outcomes and prognosis in new-onset psoriasis.","volume":"157","author":"Svedbom","year":"2021","journal-title":"JAMA Dermatol"},{"key":"zoi230227r19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/bjd.2008.159.issue-s2","article-title":"Long-term prognosis in patients with psoriasis.","volume":"159","author":"Gulliver","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"zoi230227r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.","volume":"9","author":"Strober","year":"2019","journal-title":"BMJ Open"},{"key":"zoi230227r21","doi-asserted-by":"publisher","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials.","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"zoi230227r23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(ISSN)1099-1166","article-title":"Measuring Alzheimer\u2019s disease progression with transition probabilities in the Taiwanese population.","volume":"19","author":"Fuh","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"zoi230227r24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13075-017-1289-x","article-title":"Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.","volume":"19","author":"Reed","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"zoi230227r25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.651559","article-title":"Effectiveness and efficiency of non-drug therapy among community-dwelling adults with hypertension in China: a protocol for network meta-analysis and cost-effectiveness analysis.","volume":"8","author":"Shao","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"zoi230227r26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40273-021-01034-5","article-title":"Estimation of transition probabilities for state-transition models: a review of NICE appraisals.","volume":"39","author":"Srivastava","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"zoi230227r27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials.","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"zoi230227r29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13020-018-0174-0","article-title":"Psoriasis therapy by Chinese medicine and modern agents.","volume":"13","author":"Meng","year":"2018","journal-title":"Chin Med"},{"issue":"1","key":"zoi230227r30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/09546634.2016.1178377","article-title":"Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: a systematic review.","volume":"28","author":"Parker","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"zoi230227r31","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s12325-019-00969-8","article-title":"Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis.","volume":"36","author":"Mahlich","year":"2019","journal-title":"Adv Ther"},{"issue":"1","key":"zoi230227r32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ecta.2006.74.issue-1","article-title":"Large sample properties of matching estimators for average treatment effects.","volume":"74","author":"Abadie","year":"2006","journal-title":"Econometrica"},{"key":"zoi230227r33","doi-asserted-by":"publisher","DOI":"10.1080\/03610918.2022.2118778","article-title":"Double score matching in observational studies with multi-level treatments.","author":"Zhao","year":"2022","journal-title":"Commun Stat Simul Comput"},{"issue":"3","key":"zoi230227r34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology.","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"434","key":"zoi230227r35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/01621459.1996.10476908","article-title":"Multiple imputation after 18+ years.","volume":"91","author":"Rubin","year":"1996","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"zoi230227r36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2288-9-57","article-title":"Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines.","volume":"9","author":"Marshall","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"zoi230227r37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF03325637","article-title":"Treatment of psoriasis and psoriatic arthritis.","volume":"27","author":"Papoutsaki","year":"2013","journal-title":"BioDrugs"},{"issue":"4","key":"zoi230227r38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.","volume":"310","author":"Florek","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"zoi230227r39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1468-3083.2011.04440.x","article-title":"Patient preferences for psoriasis treatments: impact of treatment experience.","volume":"27","author":"Schaarschmidt","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"zoi230227r41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jamadermatol.2021.3616","article-title":"Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the Medicare population.","volume":"157","author":"Pourali","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"28","key":"zoi230227r42","doi-asserted-by":"publisher","first-page":"46381","DOI":"10.18632\/oncotarget.v8i28","article-title":"Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients.","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"zoi230227r43","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jdv.2019.33.issue-4","article-title":"Gender and age significantly determine patient needs and treatment goals in psoriasis\u2014a lesson for practice.","volume":"33","author":"Maul","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"zoi230227r44","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaad.2008.08.028","article-title":"Psoriasis: improving adherence to topical therapy.","volume":"59","author":"Feldman","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"zoi230227r45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/jdv.2012.26.issue-s3","article-title":"Adherence to topical treatment in psoriasis: a systematic literature review.","volume":"26","author":"Devaux","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"zoi230227r46","first-page":"109","article-title":"Improving patient outcomes in psoriasis: strategies to ensure treatment adherence.","volume":"5","author":"Y\u00e9lamos","year":"2015","journal-title":"Psoriasis (Auckl)"},{"key":"zoi230227r1","volume-title":"Global Report on Psoriasis","author":"Michalek","year":"2016"},{"key":"zoi230227r22","unstructured":"He? Y. The Research and Analysis Based on the Database of Chinese Instrument for Psoriasis Assessment Tools in Clinical Trials. MD thesis. Guangzhou University of Chinese Medicine; 2015."},{"key":"zoi230227r28","unstructured":"Psoriasis Standardized Diagnosis and Treatment Center and real-world big data collection platform project launched in Beijing. 2020. Accessed November 23, 2021. https:\/\/topic.echemi.com\/a\/psoriasis-standardized-diagnosis-and-treatment-center-and-real-world-big-data-collection-platform-project-launched-in-beijing_101215.html"},{"key":"zoi230227r40","unstructured":"Biologics in practice: adherence to biologic therapy in psoriasis. Dermatologist. February 2013. Accessed December 2, 2021. https:\/\/www.hmpgloballearningnetwork.com\/site\/thederm\/site\/cathlab\/event\/biologics-practice-adherence-biologic-therapy-psoriasis"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803248\/yang_2023_oi_230227_1680032283.83265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T15:04:50Z","timestamp":1680793490000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.6795","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}